Q2 2025 Aurinia Pharmaceuticals Inc Earnings Call Transcript

Jul 31, 2025 / 12:30 PM GMT

Release Date Price: C$15.41

Transcript 10-Q8-K

Key Points

Positve

Aurinia Pharmaceuticals Inc (AUPH) reported a 22% increase in total revenue for Q2 2025, reaching $70 million, compared to the same period in 2024.
Net product sales of Lupkynis, the first FDA-approved oral therapy for lupus nephritis, increased by 21% to $66.6 million in Q2 2025.
Cash flow generated from operations was $45.5 million for the first half of 2025, a significant improvement from a negative cash flow in the same period of 2024.
The company has increased its full-year 2025 revenue guidance to a range of $260 million to $270 million, reflecting confidence in continued growth.
Aurinia Pharmaceuticals Inc (AUPH) reported positive results from its AR200 phase one study and plans to initiate further clinical studies in autoimmune diseases in the second half of the year.

Negative

Cash equivalents, restricted cash, and investments decreased to $315.1 million as of June 30, 2025, from $358.5 million at the end of 2024.
The company repurchased $11.2 million of its common shares for $90.8 million, which could impact available cash for other investments.
Despite increased revenue, the company faces competitive pressures and is not disclosing detailed plans for its AR200 development for strategic reasons.
Operating expenses remain high, with total operating expenses of $49.9 million for Q2 2025, although they have decreased from the previous year.
The company has not provided specific guidance on future operating expenses or cash flows, creating uncertainty about financial planning.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AUPH.OQ - Aurinia Pharmaceuticals Inc
Q2 2025 Aurinia Pharmaceuticals Inc Earnings Call
Jul 31, 2025 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings and welcome to the Oona Pharmaceuticals 2nd quarter 2025 earnings call.

At this time, all participants are on a listen-only mood. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press 0 on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Joe Miller, Chief Financial Officer for Orne.

Thank you. You may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.